Better predict drug's effects on human Body
New microfluidic technology, alternative to animal experimentations
Main Features
The only commercial MPS PDMS free device with no bias in toxicology and efficacy studies
Direct integration in existing analysis workflow, without disruption of the culture conditions
From 6 to 24 well allowing a direct transfer of the culture protocol
Physiological maintenance of a differentiated endothelium with an organ stroma >5 days
Our Experience
Our mission is to develop the most advanced technological platform for predicting the impact of molecules (drug, endocrine disruptor, cosmetic, etc.) on the human body to better treat pathologies (orphan diseases, cancer, bacterial resistance, virus). Moreover, This platform is an alternative to use less animals model by combining new microfluidic technology , artificial intelligence and most advanced imaging techniques.
Cubix for Pharmaceautical and Biotech Companies
- Benefits: Lower false positive drug candidate in preclinical phases, accelerate the drug development process, leading to drastic cost reduction
- How?: Obtain a functional 3D vascularized adipose tissue in medium-throughput, for a hit to lead and lead characterization
Cubix for Academic and Translational Researchers
- Benefits: New fundamental discovery leading to higher publications impact and increase Shanghai ranking
- How?: Obtain a functional 3D vascularized adipose tissue long term (> 2weeks) for new molecular target identification and mechanism of action deciphering
Diabetes Knowlegde Centre
